That, from the results of a small study. It's speculated that
enteric-coated aspirin might not be absorbed as well as plain aspirin in some
patients. This new info is questionable. Researchers only measured platelet
aggregation and not long-term outcomes.
This is more than overshadowed by big studies that show positive cardiovascular
outcomes for enteric-coated aspirin.
EC aspirin does not
have as rapid an effect on platelet function as immediate-release tablets. But
chronic use of 80 mg of EC aspirin has led to greater than 90% inhibition of
platelet cyclooxygenase.10
The weight of the evidence suggests that EC aspirin exerts antiplatelet effects.
It is too soon to
suggest that patients stop using EC aspirin. More studies will be needed to more
fully elucidate the most effective dose ranges to use, and whether or not the
enteric coating has an impact on clinical outcomes.
EITHER enteric-coated or plain aspirin can help
reduce the risk of heart attacks and strokes.
Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001:119 :300S-320S. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 1996;60:197-9.
Source: Diabetes In Control Dot Com.
Home - Table of Contents - Donate Now - About Diabetes - Warning Signs - Complications - Screening Test - Diabetes Terms - Site Search - Meet Mr. Diabetes® - Wake Up And Walk® Tour - Latest News - Headlines & News Stories - Health & Fitness - About Us - FAQ - Research Form - - Message Board - Privacy Policy - Legal Notices - How to Contact Us - Comments form - Suggestion Form - Our E-Mail Addresses - Our Address and Phone Numbers - Links - Contact Us